Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

52
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
52
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

100
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
100
Autoimmune Disorders01:29

Autoimmune Disorders

2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.6K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.6K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

16.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis.

Nature genetics·2012
Same author

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Gastroenterology·2011
Same author

Electrostatic modifications of the human leukocyte antigen DR P9 peptide-binding pocket in primary sclerosing cholangitis: back to the future with human leukocyte antigen DRβ.

Hepatology (Baltimore, Md.)·2011
Same author

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.

Nature genetics·2011
Same author

Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury.

Journal of hepatology·2010
Same author

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Nature genetics·2009

Related Experiment Video

Updated: Mar 10, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K

Genetics in autoimmune hepatitis.

Peter T Donaldson1

  • 1Lecturer in Molecular Genetics, Centre for Liver Research, School of Clinical Medical Sciences, University of Newcastle, Newcastle-upon-Tyne, United Kingdom. p.t.donaldson@ncl.ac.uk

Seminars in Liver Disease
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Autoimmune hepatitis (AIH) likely results from environmental factors interacting with host genetics. Research identifies specific gene variations, particularly in the major histocompatibility complex (MHC), influencing AIH risk and presentation.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

Related Experiment Videos

Last Updated: Mar 10, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K

Area of Science:

  • Immunology
  • Genetics
  • Hepatology

Background:

  • Autoimmune hepatitis (AIH) is hypothesized to arise from environmental triggers in genetically predisposed individuals.
  • Genetic susceptibility involves a complex interplay of multiple genes, influencing both disease risk and clinical phenotype.
  • Previous research has primarily focused on the major histocompatibility complex (MHC) region for AIH type 1 susceptibility.

Purpose of the Study:

  • To review and synthesize current hypotheses regarding the genetic underpinnings of autoimmune hepatitis (AIH).
  • To explore proposed molecular models within the MHC DRB1 region associated with AIH susceptibility.
  • To identify potential non-MHC genetic risk factors for AIH.

Main Methods:

  • Review of existing literature on genetic associations with autoimmune hepatitis type 1.
  • Analysis of proposed molecular models based on specific amino acid residues within the MHC DRB1 region.
  • Examination of studies investigating genetic polymorphisms outside the MHC, such as CTLA4.

Main Results:

  • Three distinct molecular models (histidine at DRbeta13, lysine at DRbeta71, valine at DRbeta86) have been proposed for MHC-linked AIH susceptibility.
  • The lysine-71 model shows broader applicability across different populations compared to DRbeta13 and DRbeta86 models.
  • The CTLA4 A+49G (G allele) has been identified as a potential secondary risk allele outside the MHC.

Conclusions:

  • The observed variations in MHC associations may reflect population-specific genetic backgrounds and the 'molecular footprint' of environmental triggers.
  • Multiple genetic loci likely contribute to AIH pathogenesis, necessitating further research to identify additional disease alleles.
  • Comprehensive genomic studies are crucial for a complete understanding of AIH genetic architecture.